These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9667249)

  • 1. Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas.
    Wilson WH; Little R; Pearson D; Jaffe ES; Steinberg SM; Cheson BD; Humphrey R; Kohler DR; Elwood P
    J Clin Oncol; 1998 Jul; 16(7):2345-51. PubMed ID: 9667249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients.
    Dahut W; Harold N; Takimoto C; Allegra C; Chen A; Hamilton JM; Arbuck S; Sorensen M; Grollman F; Nakashima H; Lieberman R; Liang M; Corse W; Grem J
    J Clin Oncol; 1996 Apr; 14(4):1236-44. PubMed ID: 8648379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma.
    Argiris A; Heald P; Kuzel T; Foss FM; DiStasio S; Cooper DL; Arbuck S; Murren JR
    Invest New Drugs; 2001; 19(4):321-6. PubMed ID: 11561692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
    Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
    J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
    Sewak S; Sorich J; O'Leary J
    Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
    Pitot HC; Knost JA; Mahoney MR; Kugler J; Krook JE; Hatfield AK; Sargent DJ; Goldberg RM
    Cancer; 2000 Oct; 89(8):1699-705. PubMed ID: 11042563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
    Bartlett NL; Johnson JL; Wagner-Johnston N; Ratain MJ; Peterson BA;
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):793-8. PubMed ID: 18648813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
    Wilson WH; Chabner BA; Bryant G; Bates S; Fojo A; Regis J; Jaffe ES; Steinberg SM; Goldspiel BR; Cheson BD
    J Clin Oncol; 1995 Feb; 13(2):381-6. PubMed ID: 7531220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma.
    Pazdur R; Diaz-Canton E; Ballard WP; Bradof JE; Graham S; Arbuck SG; Abbruzzese JL; Winn R
    J Clin Oncol; 1997 Aug; 15(8):2905-9. PubMed ID: 9256134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
    Vokes EE; Gordon GS; Rudin CM; Mauer AM; Watson S; Krauss S; Arrieta R; Golomb HM; Hoffman PC
    Invest New Drugs; 2001; 19(4):329-33. PubMed ID: 11561694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes A; Romaguera J; Mesina O; Hagemeister F; Sarris AH; Rodriguez MA; McLaughlin P; Preti HA; Bachier C; Cabanillas F
    Br J Haematol; 1998 Dec; 103(3):678-83. PubMed ID: 9858216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
    Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
    J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
    Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.